Research Progress of Primary Non-response to Anti-TNF-α Monoclonal Antibody in Patients with Inflammatory Bowel Disease

Anti-tumor necrosis factor-a(anti-TNF-a) monoclonal antibodies are now widely used in patients with steroid-dependent or steroid-refractory inflammatory bowel disease(IBD). However, some patients will experience primary non-response(PNR) during treatment. This review summarized the current research progress on the mechanism and predictive markers of PNR in IBD patients treated with anti-TNF-α monoclonal antibodies, providing a theoretical basis for the realization of precise and individualized treatment of IBD biologics.